Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer: a systematic review.

About this Publication
Title
Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer: a systematic review.
Pubmed ID
21409528 (View this publication on the PubMed website)
Publication
Cancer Causes Control. 2011 May; Volume 22 (Issue 5): Pages 803-10
Authors
Wilson JC, Anderson LA, Murray LJ, Hughes CM
Affiliations
  • Centre for Public Health, School of Medicine Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. jwilson57@qub.ac.uk
Abstract

BACKGROUND: Use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with a reduced risk of several cancers. This is thought to be through the inhibitory action on the cyclooxygenase (COX) enzyme, COX-2. Evidence for NSAIDs preventing head and neck cancer (HNC) is conflicting. We conducted a systematic literature review to investigate the association between NSAID/aspirin use and risk of head and neck cancer (HNC).

METHODOLOGY: MEDLINE, EMBASE, PubMed, Cochrane Library, and Web of Science were systematically searched using terms for NSAIDs/aspirin, HNC, and observational/intervention study designs to identify studies published by December 2009.

RESULTS: Of 9,268 articles identified, two population-based prescribing database studies and three case-control studies met the selection criteria. The studies investigated different HNC sites. Only one study found a significant protective association of aspirin use with HNC risk (OR 0.75, 95% CI 0.58-0.96), and one showed a significantly increased risk of oral/oropharyngeal cancer with non-low-dose aspirin NSAID use (OR 3.5, 95% CI 1.8-6.7). Many of the studies identified lacked information on important confounding factors.

CONCLUSION: No definitive conclusion on the effect of NSAIDs/aspirin on HNC risk was possible. Aspirin may protect against HNC, although further robust large-scale studies are required to clarify any possible association.

Related CDAS Studies
Related CDAS Projects